Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Research feed

This week in peptide research

Every new PubMed record and registered trial naming a compound in the library, linked to the source, labelled by study type and model.

44 studies · 52 entry changes

New studies

Changes to our entries

  • Pentadeca arginate (PDA) · Oct 24, 2026

    New research reference added: Pentadeca arginate (PDA).

  • TB-500 · Oct 24, 2026

    Removed a ClinicalTrials.gov record (NCT07487363) that its sponsor describes as an example, not a real study.

  • MOTS-c · Oct 24, 2026

    Removed a ClinicalTrials.gov record (NCT07505745) that its sponsor describes as an example, not a real study.

  • BPC-157 · Oct 24, 2026

    Removed a ClinicalTrials.gov record (NCT07437547) that its sponsor describes as an example, not a real study.

  • GHK-Cu · Oct 24, 2026

    Removed a ClinicalTrials.gov record (NCT07437586) that its sponsor describes as an example, not a real study.

  • Tesofensine · Oct 24, 2026

    WADA class corrected: tesofensine is listed under S6.B (specified stimulants), not S6.A.

  • Apelin-13 · Oct 24, 2026

    New research reference added: Apelin-13.

  • Thymulin · Oct 24, 2026

    New research reference added: Thymulin.

  • MariTide (maridebart cafraglutide) · Oct 24, 2026

    New research reference added: MariTide (maridebart cafraglutide).

  • Ecnoglutide · Oct 24, 2026

    New research reference added: Ecnoglutide.

  • Matrixyl · Oct 24, 2026

    New research reference added: Matrixyl.

  • Argireline · Oct 24, 2026

    New research reference added: Argireline.

  • Adipotide · Oct 24, 2026

    New research reference added: Adipotide.

  • Triptorelin · Oct 24, 2026

    New research reference added: Triptorelin.

  • Abaloparatide · Oct 24, 2026

    New research reference added: Abaloparatide.

  • Leuprolide · Oct 24, 2026

    New research reference added: Leuprolide.

  • Thymosin beta-4 · Oct 24, 2026

    New research reference added: Thymosin beta-4.

  • Orforglipron · Oct 24, 2026

    New research reference added: Orforglipron.

  • hCG (human chorionic gonadotropin) · Oct 24, 2026

    New research reference added: hCG (human chorionic gonadotropin).

  • Octreotide · Oct 24, 2026

    New research reference added: Octreotide.

  • Setmelanotide · Oct 24, 2026

    New research reference added: Setmelanotide.

  • Teduglutide · Oct 24, 2026

    New research reference added: Teduglutide.

  • Larazotide · Oct 24, 2026

    New research reference added: Larazotide.

  • Dulaglutide · Oct 24, 2026

    New research reference added: Dulaglutide.

  • Exenatide · Oct 24, 2026

    New research reference added: Exenatide.

  • Pramlintide · Oct 24, 2026

    New research reference added: Pramlintide.

  • Teriparatide · Oct 24, 2026

    New research reference added: Teriparatide.

  • Vasopressin · Oct 24, 2026

    New research reference added: Vasopressin.

  • Oxytocin · Oct 23, 2026

    Added week-by-week schedules from the FDA label (1 group, 1 arms).

  • Retatrutide · Oct 23, 2026

    Added week-by-week schedules from registered trials (5 groups, 21 arms).

  • Survodutide · Oct 23, 2026

    Added week-by-week schedules from registered trials (5 groups, 15 arms).

  • Cagrilintide · Oct 23, 2026

    Added week-by-week schedules from registered trials (1 group, 5 arms).

  • Mazdutide · Oct 23, 2026

    Added week-by-week schedules from registered trials (3 groups, 7 arms).

  • Eloralintide · Oct 23, 2026

    Added week-by-week schedules from registered trials (1 group, 6 arms).

  • Amycretin · Oct 23, 2026

    Added week-by-week schedules from registered trials (3 groups, 13 arms).

  • Pemvidutide · Oct 23, 2026

    Added week-by-week schedules from registered trials (1 group, 2 arms).

  • VK2735 · Oct 23, 2026

    Added week-by-week schedules from registered trials (1 group, 4 arms).

  • Tesofensine · Oct 23, 2026

    Added week-by-week schedules from registered trials (1 group, 3 arms).

  • ARA-290 · Oct 23, 2026

    Added week-by-week schedules from registered trials (1 group, 3 arms).

  • VIP · Oct 23, 2026

    Added week-by-week schedules from registered trials (2 groups, 2 arms).

  • PT-141 · Oct 23, 2026

    Added week-by-week schedules from the FDA label (1 group, 1 arms).

  • Afamelanotide · Oct 23, 2026

    Added week-by-week schedules from the FDA label (1 group, 1 arms).

  • Tesamorelin · Oct 23, 2026

    Added week-by-week schedules from the FDA label (1 group, 2 arms).

  • Liraglutide · Oct 23, 2026

    Added week-by-week schedules from the FDA label (2 groups, 4 arms).

  • Tirzepatide · Oct 23, 2026

    Added week-by-week schedules from the FDA label (2 groups, 5 arms).

  • Semaglutide · Oct 23, 2026

    Added week-by-week schedules from the FDA label (4 groups, 11 arms).

  • Tesofensine · Oct 23, 2026

    Re-cited the half-life to the population pharmacokinetic study that measured it (Alzheimer patients).

  • Mazdutide · Oct 23, 2026

    Re-cited the half-life to the phase 1b study that measured it.

  • Cagrilintide · Oct 23, 2026

    Re-cited the half-life to the phase 1b study that measured it, and noted it was measured alongside semaglutide.

  • ARA-290 · Oct 23, 2026

    Corrected the phase 2 amounts: no phase 2 trial gave 2 mg per day; the 2 mg amount was intravenous, in a pilot and a healthy-volunteer study.

  • Retatrutide · Oct 23, 2026

    Corrected the phase 2 treatment duration from 24–48 weeks to 36–48 weeks; 24 weeks was only the primary endpoint of the type 2 diabetes trial.

  • Semaglutide · Oct 23, 2026

    Corrected which label each amount is cited to: tablet amounts now cite the Rybelsus/Ozempic tablets label and Wegovy amounts the Wegovy label.

Full change log →

Filed automatically from PubMed and ClinicalTrials.gov when a library compound's name appears in the title or abstract; study type and model come from the index record, not from reading the paper. Inclusion is not an endorsement.